Compare GeneDx Holdings Corp (WGS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Xylem, Inc. — how do they compare? GeneDx Holdings Corp trades at $82.71 (market cap $2.44B), while Xylem, Inc. trades at $121.4 (market cap $28.76B). The key difference: Xylem, Inc. is far larger — about 11.8× GeneDx Holdings Corp's market cap, and Xylem, Inc. pays a 1.4% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| WGS | XYL | |
|---|---|---|
Market Cap | $2.44B | $28.76B |
Sector | Technology | Industrials |
52-Week High | $167.51 | $152.95 |
52-Week Low | $34.51 | $106.34 |
Enterprise Value | $2.48B | $30.54B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Xylem (XYL) trades at $121.87, up 0.56% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. The company's fundamentals show robust revenue growth, expanding margins, and healthy cash flow, supported by strategic acquisitions like Cornell Pump and Roper Pump to bolster its industrial water technology presence. Analyst consensus is mixed but leans positive, with a $150.43 price target implying significant upside.
Outlook remains favorable due to secular demand in water infrastructure and AI-driven data centers, though risks include execution on acquisitions and economic sensitivity. The stock offers growth potential from margin expansion and digital water solutions, but investors should monitor integration challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
